These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38758884)

  • 1. Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B.
    Liu R; Qiao J; Zhang L; Dou Z
    Medicine (Baltimore); 2024 May; 103(20):e37953. PubMed ID: 38758884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.
    Li B; Liu Z; Liu X; Liu D; Duan M; Gu Y; Liu Q; Ma Q; Wei Y; Wang Y
    Hepatol Int; 2021 Oct; 15(5):1103-1108. PubMed ID: 34312798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
    Chiu SM; Chang KC; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
    Dig Dis Sci; 2023 Feb; 68(2):665-675. PubMed ID: 35976597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate.
    Byun KS; Choi J; Kim JH; Lee YS; Lee HC; Kim YJ; Yoo BC; Kwon SY; Gwak GY; Lim YS
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):427-437.e5. PubMed ID: 33962041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Agarwal K; Brunetto M; Seto WK; Lim YS; Fung S; Marcellin P; Ahn SH; Izumi N; Chuang WL; Bae H; Sharma M; Janssen HLA; Pan CQ; Çelen MK; Furusyo N; Shalimar D; Yoon KT; Trinh H; Flaherty JF; Gaggar A; Lau AH; Cathcart AL; Lin L; Bhardwaj N; Suri V; Mani Subramanian G; Gane EJ; Buti M; Chan HLY; ;
    J Hepatol; 2018 Apr; 68(4):672-681. PubMed ID: 29756595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
    Liu Z; Zhao Z; Ma X; Liu S; Xin Y
    BMC Gastroenterol; 2023 Nov; 23(1):384. PubMed ID: 37950196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
    Jeong S; Shin HP; Kim HI
    Intervirology; 2022; 65(2):94-103. PubMed ID: 34731856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B.
    Nam H; Han JW; Lee SK; Yang H; Lee HL; Sung PS; Song MJ; Kwon JH; Jang JW; Chang UI; Kim CW; Nam SW; Bae SH; Choi JY; Yoon SK; Yang JM; Kim HY
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1673-1683. PubMed ID: 38690711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.
    Pan CQ; Chang TT; Bae SH; Brunetto M; Seto WK; Coffin CS; Tan SK; Mo S; Flaherty JF; Gaggar A; Nguyen MH; Çelen MK; Thompson A; Gane EJ
    PLoS One; 2021; 16(5):e0251552. PubMed ID: 33984038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B.
    Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
    J Viral Hepat; 2021 Nov; 28(11):1570-1578. PubMed ID: 34435412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A study of the effectiveness of nucleos(t)ide analogues in the treatment of HBeAg- positive chronic hepatitis B with normal alanine aminotransferase and high level of HBV DNA].
    Wang FD; Zhou J; Zhang DM; Wang ML; Tao YC; Wu DB; Tang H; Chen EQ
    Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):389-394. PubMed ID: 35545563
    [No Abstract]   [Full Text] [Related]  

  • 12. Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes.
    Chen HL; Lee CN; Chang CH; Lai MW; Tsai MC; Mu SC; Liu CJ; Shih JC; Wen WH; Hu RT; Huang CP; Hu KC; Chen CP; Lee CL; Chien RN; Chang KC; Hsu HY; Lee CC; Ni YH; Chang MH
    Liver Int; 2024 Jun; 44(6):1422-1434. PubMed ID: 38456620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece.
    Sinakos E; Kachru N; Tsoulas C; Jeyakumar S; Smith NJ; Yehoshua A; Cholongitas E
    J Comp Eff Res; 2024 Apr; 13(4):e230090. PubMed ID: 38317634
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
    Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
    Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Kim K; Kitrinos KM; Subramanian GM; McHutchison JG; Yee LJ; Elkhashab M; Berg T; Sporea I; Yurdaydin C; Husa P; Jablkowski MS; Gane E
    J Hepatol; 2017 Jan; 66(1):11-18. PubMed ID: 27545497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study.
    Zhang Q; Xu J; Liu D; Wang L; Ren S; Zheng S; Chen X; Qi L; Lu J
    Antivir Ther; 2024 Oct; 29(5):13596535241284226. PubMed ID: 39259839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia].
    Liu LP; Wu XP; Cai TP; Wang L; Sun J; Liang JY; Ma SP; Gan X; Ruan NH; Ge SF
    Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):118-125. PubMed ID: 37137825
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical Efficacy and Safety of Long-Term Treatment of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate for Chronic Hepatitis B in Vietnam.
    Huynh Phuong Nguyen T; Thi Huong Bui Q; Duy Vo T
    Clin Transl Gastroenterol; 2024 Oct; 15(10):e1. PubMed ID: 38994860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.
    Chan HLY; Buti M; Lim YS; Agarwal K; Marcellin P; Brunetto M; Chuang WL; Janssen HLA; Fung S; Izumi N; Abdurakhmanov D; Jabłkowski M; Celen MK; Ma X; Caruntu F; Flaherty JF; Abramov F; Wang H; Camus G; Osinusi A; Pan CQ; Shalimar ; Seto WK; Gane E;
    Am J Gastroenterol; 2024 Mar; 119(3):486-496. PubMed ID: 37561058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.
    Kovari H; Surial B; Tarr PE; Cavassini M; Calmy A; Schmid P; Bernasconi E; Rauch A; Wandeler G; Ledergerber B;
    HIV Med; 2021 Aug; 22(7):623-628. PubMed ID: 33880839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.